Cibc World Market Inc. grew its position in Royalty Pharma PLC (NASDAQ:RPRX – Free Report) by 46.2% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 120,661 shares of the biopharmaceutical company’s stock after purchasing an additional 38,114 shares during the quarter. Cibc World Market Inc.’s holdings in Royalty Pharma were worth $7,042,000 as of its most recent filing with the SEC.
Several other large investors also recently modified their holdings of RPRX. Edgestream Partners L.P. bought a new stake in Royalty Pharma during the third quarter valued at $5,049,000. Teachers Retirement System of The State of Kentucky bought a new position in shares of Royalty Pharma in the 3rd quarter worth about $24,225,000. Hantz Financial Services Inc. lifted its stake in shares of Royalty Pharma by 22,183.3% in the 3rd quarter. Hantz Financial Services Inc. now owns 51,920 shares of the biopharmaceutical company’s stock valued at $3,030,000 after purchasing an additional 51,687 shares during the period. Ground Swell Capital LLC acquired a new position in shares of Royalty Pharma in the 3rd quarter valued at about $401,000. Finally, Danske Bank A S boosted its position in shares of Royalty Pharma by 44.4% during the 3rd quarter. Danske Bank A S now owns 1,107,117 shares of the biopharmaceutical company’s stock valued at $64,611,000 after purchasing an additional 340,439 shares in the last quarter. 54.35% of the stock is currently owned by institutional investors and hedge funds.
Analyst Ratings Changes
Several research firms recently commented on RPRX. JPMorgan Chase & Co. raised their target price on Royalty Pharma from $58.00 to $62.00 and gave the stock an “overweight” rating in a research note on Friday, August 7th. TD Cowen boosted their price target on Royalty Pharma from $68.00 to $80.00 and gave the company a “buy” rating in a research note on Wednesday. Bank of America restated a “buy” rating on shares of Royalty Pharma in a report on Wednesday, August 5th. The Goldman Sachs Group reaffirmed a “buy” rating and set a $66.00 price objective on shares of Royalty Pharma in a research report on Thursday, August 6th. Finally, Citigroup lifted their price objective on shares of Royalty Pharma from $70.00 to $78.00 and gave the company a “buy” rating in a research note on Thursday, November 5th. One research analyst has rated the stock with a Strong Buy rating and eight have given a Buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $65.00.
Royalty Pharma Stock Performance
NASDAQ RPRX opened at $68.47 on Friday. The company has a fifty day moving average price of $62.31 and a 200-day moving average price of $55.20. The firm has a market cap of $39.28 billion, a price-to-earnings ratio of 57.06, a PEG ratio of 1.35 and a beta of 0.37. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.29 and a quick ratio of 1.29. Royalty Pharma PLC has a 1 year low of $37.31 and a 1 year high of $70.37.
Royalty Pharma Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Shareholders of record on Friday, November 13th will be paid a $0.2350 dividend. The ex-dividend date is Friday, November 13th. This represents a $0.94 annualized dividend and a yield of 1.4%. Royalty Pharma’s dividend payout ratio (DPR) is 78.33%.
Insider Buying and Selling at Royalty Pharma
In other news, EVP Christopher Hite sold 100,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 17th. The stock was sold at an average price of $68.15, for a total value of $6,815,000.00. Following the transaction, the executive vice president owned 177,523 shares in the company, valued at $12,098,192.45. The trade was a 36.03% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Terrance P. Coyne sold 232,536 shares of the company’s stock in a transaction that occurred on Monday, November 16th. The shares were sold at an average price of $68.87, for a total value of $16,014,754.32. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 440,788 shares of company stock worth $29,157,162. Insiders own 18.84% of the company’s stock.
Royalty Pharma Company Profile
Royalty Pharma plc is a biopharmaceutical royalty company that provides funding to companies and inventors in exchange for royalty interests in medicines. It acquires existing royalties and helps finance drug development and commercialization through royalty-based transactions and other forms of funding. The company’s portfolio includes royalty interests in medicines across a range of therapeutic areas, spanning both approved treatments and products in development. Royalty Pharma generally earns revenue when these medicines are sold; it does not operate as a conventional drug manufacturer or commercialize medicines itself.
Featured Stories
- Five stocks we like better than Royalty Pharma
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Royalty Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Royalty Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
